Today's data were certainly good. I was worried that the numbers reported in February wouldn't hold up, but they have and the numbers for measurable disease response and for patients experiencing a 50% or greater decline in PSA have improved, while the percentage of patients who were progression-free at 12 weeks has stayed about the same. Also, they're now reporting that of the 4 out of 9 patients in the 427 + prednisone arm who had a measurable disease response (vs. 0 out of 12 in the prednisone alone arm), one had a complete response.
Granted, the number of patients reported on has only increased from 32 in February to 42, but they've now enrolled 64 of the planned 72 patients so maybe they'll have more complete data by the end of the year.
Given the dismal market and the likelihood that some people are selling on the ASCO news, I guess it's not a surprise that the stock hasn't reacted favorably. Plus there hasn't been much analyst buzz about OGXI at ASCO. Hopefully there will be a little now.